UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI

Size: px
Start display at page:

Download "UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI"

Transcription

1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. GSK Medicine: Umeclidinium mcg, Vilanterol mcg, and Umeclidinium/Vilanterol / mcg Study Number: DB Title: A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium mcg, Vilanterol mcg, and Umeclidinium/Vilanterol / mcg Once- Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Rationale: The purpose of this study was to evaluate the lung function response to,, and in individual patients using a cross-over design. This allowed evaluation of response in patients who demonstrated a response 12% and 200 ml to either or to determine if additional benefit was provided by. Phase: IIIb Study Period: 19 Oct Mar 2013 Study Design: This was a multicenter, randomized, double-blind, three-way, complete block, cross-over study. Eligible subjects were randomized to 1 of 6 treatment sequences. The study consisted of 14 clinic visits conducted on an outpatient basis. Subjects signed the informed consent form (ICF) at Visit 0 and were assigned a subject identifier. Subjects who met the eligibility criteria at screening (Visit 1) completed a 5- to 7-day run-in period prior to randomization. The treatment phase comprised three 14-day treatment periods, each separated by a 10- to 14-day washout period starting on Day 15. A follow-up phone call for adverse event (AE) assessment occurred 7 to 9 days after completion of the final clinic visit or premature discontinuation. The total duration of subject participation in the study was approximately 12 weeks. Centres: 16 centers in Germany and 5 centers in Estonia Indication: Chronic Obstructive Pulmonary Disease Treatment: Subjects received each of the following treatments, in random order, taken for 14 days: Inhalation Powder mcg once-daily. Inhalation Powder mcg once-daily. Inhalation Powder / mcg once-daily. Objectives: The primary objective of this study was to evaluate the lung function response following treatment with mcg, mcg, and / mcg administered once-daily via the Novel Dry Powder Inhaler (NDPI) in subjects with COPD Primary Outcome/Efficacy Variable: Weighted mean forced expiratory volume in 1 second (FEV1) over 0-6 hours post-dose on Day 14 of each treatment period Secondary Outcome/Efficacy Variable(s): Proportion of subjects who were responsive to, or according to FEV1 at Day 1 (responsive defined as an increase from baseline of at least 12% and 200mL at any time over 0-6 h post-dose) Proportion of subjects who had a larger change from baseline in 0-6 hour weighted mean FEV1 on Day 14 with compared with and alone Trough FEV1 on Day 15 Statistical Methods: The primary analyses were in the subgroup of subjects who responded to or the subgroup of subjects who responded to, where response was defined as an increase of 12% and 200 ml above baseline for FEV1 during the 0-6 h post-dose period on Day 1. It was anticipated that 50% of subjects would respond to and 50% would respond to. Therefore, approximately 172 subjects were to be randomized to provide 146 completers, which would give sufficient power for comparisons in these subgroups. The following treatment comparisons were initially performed for the primary endpoint of 0-6 hour weighted mean FEV1 on Day 14, for the ITT Population. vs. in subjects who responded to vs. in subjects who responded to To account for multiplicity across treatment comparisons a step-down testing procedure was applied whereby inference for the second treatment comparison was dependent on statistical significance at the 5% level having been achieved for the first comparison. Other treatment comparisons were considered exploratory and no multiplicity 1

2 adjustment was applied. The primary analysis of change from baseline in 0-6 hour weighted mean FEV1 on Day 14 was performed using an analysis of covariance (ANCOVA) model. Data from all subjects were used by including a type of response (,, neither) in the model along with other predefined effects including period baseline FEV1, mean baseline FEV1 and period. Subject was fitted as a random effect. The proportion of subjects who were responders according to FEV1 on Day 1 were analysed using a logistic regression model including treatment, period baseline FEV1, mean baseline FEV1 and period fitted as fixed effects and subjects as a random effect. The proportion of subjects who showed a larger change from baseline in 0-6 h weighted mean FEV1 on Day 14 on vs. were tested to see if it was different from 50% using the McNemar/sign test. This analysis was supported by cumulative distribution function plots of the vs. difference in change from baseline in 0-6 h weighted mean FEV1 on Day 14. The analysis and figure were repeated for vs.. Trough FEV1 was reported in the same way as the primary endpoint (on ITT subjects only). Study Population: Male subjects and female subjects of non-childbearing potential or female subjects of childbearing potential who agreed to acceptable contraceptive methods who had an established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society were included if they were 40 years of age at Visit 1. Subjects had a pre- and post-salbutamol FEV1/forced vital capacity (FVC) ratio of <0.70 and a pre- and post-salbutamol FEV1 of 70% of predicted normal values at Visit 1 calculated using Nutrition Health and Examination Survey (NHANES) III reference equations. Subjects were current or former cigarette smokers with a history of cigarette smoking of 10 pack-years at Visit 1. Concurrent use of inhaled corticosteroids (ICS) at a dose of up to 1000 mcg/day of fluticasone propionate or equivalent was permitted during the study provided the dose remained consistent throughout the study. ITT Population Number of Subjects: Planned, N 172 Randomised, N 182 Completed, n (%) 159 (87) Total Number Subjects Withdrawn, N (%) 23 (13) Withdrawn due to Adverse Events n (%) 6 (3) Withdrawn due to Lack of Efficacy n (%) 4 (2) Withdrawn for other reasons n (%) 13 (7) Demographics ITT Population N (ITT) 182 Females: Males 55/127 Mean Age, years (SD) 63.2 (8.19) White, n (%) 182 (100) Mean Height (SD), cm (8.59) Mean Weight (SD), kg 81.0 (17.07) Mean Body Mass Index (SD), kg/m (4.953) Primary Efficacy Results: 0-6 Hour Weighted Mean FEV1 (L) at Day 14 by Response Type / 2

3 Responder to Only n LS mean (SE) (0.0166) (0.0167) (0.0166) LS mean change (SE) (0.0166) (0.0167) (0.0166) / vs Column Difference % CI (0.085,0.157) (0.100,0.171) p-value <0.001 <0.001 Responder to Only n LS mean (SE) (0.0150) (0.0147) (0.0148) LS mean change (SE) (0.0150) (0.0147) (0.0148) / vs Column Difference % CI (0.110,0.174) (0.067,0.130) p-value <0.001 <0.001 Responder to Neither n LS mean (SE) (0.0243) (0.0240) (0.0243) LS mean change (SE) (0.0243) (0.0240) (0.0243) / vs Column Difference % CI (0.001,0.104) (0.021,0.124) p-value Hour Weighted Mean FEV1 (L) at Day 14 (Entire ITT Population) / Day 14 n LS mean (SE) (0.0135) (0.0134) (0.0134) LS mean change (SE) (0.0135) (0.0134) (0.0134) / vs Column Difference % CI (0.090,0.139) (0.078,0.127) p-value <0.001 <0.001 Secondary Outcome Results: Proportion of Subjects Who Were Responsive According to FEV1 at Day 1 / 3

4 n Responder, n (%) 92 (54) 104 (61) 124 (72) Non-Responder, n (%) 79 (46) 67 (39) 49 (28) / vs Column Odds Ratio % CI (1.40, 3.58) (0.90, 2.32) Proportion of Subjects Who Had a Larger Change from Baseline in 0-6 Hour Weighted Mean FEV1 at Day 14 with Compared with and Alone n Improved on, n (%) 113 (70) 121 (74) Not Improved, n (%) 49 (30) 42 (26) Trough FEV1 at Day 15 by Response Type / Responder n LS mean (SE) (0.0178) (0.0180) (0.0179) LS mean change (SE) (0.0178) (0.0180) (0.0179) / vs Column Difference % CI (0.043,0.124) (0.067,0.148) Responder n LS mean (SE) (0.0160) (0.0158) (0.0159) LS mean change (SE) (0.0160) (0.0158) (0.0159) / vs Column Difference % CI (0.097,0.170) (0.071,0.142) Responder to Neither n LS mean (SE) (0.0263) (0.07) (0.0260) LS mean change (SE) (0.0263) (0.07) (0.0260) / vs Column Difference % CI (-0.027,0.090) (-0.001,0.114) Trough FEV1 at Day 15 (Entire ITT Population) / Day 15 n LS mean (SE) (0.0132) (0.0131) (0.0131) LS mean change (SE) (0.0132) (0.0131) (0.0131) / vs Column Difference % CI (0.065,0.120) (0.067,0.122) Safety Results: An on therapy adverse event (AE) was defined as an AE with onset on or after the start date of study medication but not later than the last contact date. AEs with onset during the wash-out or follow-up periods were 4

5 considered on-treatment and were assigned to the treatment received in the previous period. An on therapy serious adverse event (SAE) was defined as a SAE with onset on or after the start date of study medication and up to the last contact date. / Most Frequent Adverse Events On-Therapy n (%) n (%) n (%) 5

6 Subjects with any AE(s), n(%) 28 (16) 30 (18) 32 (18) Nasopharyngitis 5 (3) 11 (6) 7 (4) Headache 3 (2) 2 (1) 6 (3) Dyspnea 2 (1) 1 (<1) 0 Chronic Obstructive Pulmonary Disease 2 (1) 0 0 Pyrexia 2 (1) 2 (1) 1 (<1) Back Pain 2 (1) 0 1 (<1) Rhinitis 1 (<1) 1 (<1) 2 (1) Cough 1 (<1) 1 (<1) 3 (2) Gastroenteritis norovirus 1 (<1) 0 0 Herpes Zoster 1 (<1) 0 0 Otitis Media 1 (<1) 0 0 Oropharyngeal Pain 1 (<1) 1 (<1) 0 Wheezing 1 (<1) 0 0 Radiculitis lumbrosacral 1 (<1) 0 0 Abdominal pain upper 1 (<1) 0 0 Gastritis 1 (<1) 0 0 Gastroesophageal reflux disease 1 (<1) 0 0 Toothache 1 (<1) 0 0 Arthralgia 1 (<1) 0 0 Decreased appetite 1 (<1) 1 (<1) 0 Hyperglycemia 1 (<1) 0 0 Thermal burn 1 (<1) 0 0 Anxiety 1 (<1) 0 0 Cataract 1 (<1) 0 0 Esophageal carcinoma 1 (<1) 0 0 Pancreatic carcinoma 1 (<1) 0 0 Hypertension 1 (<1) 0 0 Diarrhea 0 3 (2) 0 Bronchitis 0 1 (<1) 0 Candidiasis 0 1 (<1) 0 Pneumonia 0 1 (<1) 0 Viral infection 0 1 (<1) 0 Dysphonia 0 1 (<1) 0 Throat irritation 0 1 (<1) 0 Upper respiratory tract inflammation 0 1 (<1) 0 Dizziness 0 1 (<1) 0 Edema peripheral 0 1 (<1) 0 Gout 0 1 (<1) 0 Type 2 diabetes mellitus 0 1 (<1) 0 Sinus tachycardia 0 1 (<1) 0 Tachyarrhythmia 0 1 (<1) 0 Spinal fracture 0 1 (<1) 0 Aggression 0 1 (<1) 0 Depression 0 1 (<1) 0 Photophobia 0 1 (<1) 0 Gamma-glutamyltransferase increased 0 1 (<1) 0 Weight increased 0 1 (<1) 0 Abscess limb (<1) Gastroenteritis (<1) Gastroenteritis viral (<1) Gingivitis (<1) Oral fungal infection (<1) Pharyngitis (<1) Upper respiratory tract infection (<1) 6

7 Urinary tract infection (<1) Epistaxis (<1) Paresthesia (<1) Abdominal pain (<1) Chest pain (<1) Myalgia (<1) Osteoarthritis (<1) Hypercholesterolemia (<1) Angina pectoris (<1) Tachycardia (<1) Contusion (<1) Bladder cancer (<1) Serious Adverse Events - On-Therapy n (%) [n considered by the investigator to be related to study medication] / n (%) [related] n (%) [related] n (%) [related] Subjects with any SAE(s), n (%) [number related] 3 (2) [1] 1 (<1) [0] 3 (2) [0] Includes both fatal and non-fatal events Bladder cancer (<1) [0] Oesophageal carcinoma 1 (<1) [0] 0 0 Pancreatic carcinoma 1 (<1) [0] 0 0 Chronic Obstructive Pulmonary Disease 2 (1) [1] 0 0 Angina pectoris (<1) [0] Abscess limb (<1) [0] Spinal fracture 0 1 (<1) [0] 0 / n (%) [related] n (%) [related] n (%) [related] Subjects with fatal SAEs, n (%) [number related] 1 (<1) [0] 0 [0] 0 [0] Oesophageal carcinoma 1 (<1) [0] 0 0 Pancreatic carcinoma 1 (<1) [0] 0 0 Conclusion: Subjects identified as responders to or demonstrated statistically significantly greater improvement in lung function (0-6 hour weighted mean FEV1 and trough FEV1) with / compared with or alone. Non-responders to or also showed greater improvements in lung function with / compared with either component alone. In the ITT Population, treatment differences were greater with / compared with components. In the ITT Population, 16% of subjects had AEs in the treatment period, 18% of subjects had AEs in the treatment period, and 18% of subjects had AEs in the / treatment period. The most commonly reported AEs were nasopharyngitis and headache in the and / periods, and nasopharyngitis and diarrhea in the treatment period. On-treatment SAEs were reported by 2% of subjects in the / treatment period, 2% of subjects in the treatment period and by <1% of subjects during the treatment period. COPD was the only SAE reported in more than one subject. 7

8 One subject (<1%) had a fatal event (oesophageal carcinoma/pancreatic carcinoma) in the study that occurred during the treatment period that was not considered related to study drug by the investigator. 8

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1)

Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate () (mcg strength) bd via DISKUS/ACCUHALER

More information

Study No.: SFCA3007 Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS

Study No.: SFCA3007 Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS Study No.: A3007 Title: A Randomized, Double-Blind, -Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres).

SYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres). Drug product: Symbicort Turbuhaler Drug substance(s): ST (Symbicort Turbuhaler ) Edition No.: 1.0 Study code: D5890C00010 Date: 15 March 2007 SYNOPSIS An 8-week, randomised, double blind, parallel-group,

More information

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Secondary Outcome/Efficacy Variable(s):

Secondary Outcome/Efficacy Variable(s): The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Secondary efficacy endpoints for Part 2, the Eltrombopag-Only Period, included the proportion of subjects who

Secondary efficacy endpoints for Part 2, the Eltrombopag-Only Period, included the proportion of subjects who The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating

More information

umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline

umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement

Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix JF Herth, Chau Thach, Robert Fogel, Petter Olsson,

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Evidence Summary to support COPD formulary decision making and guideline development

Evidence Summary to support COPD formulary decision making and guideline development Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final page of this document. Trelegy and Ellipta

More information

Study No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):

Study No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s): Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

mg 25 mg mg 25 mg mg 100 mg 1

mg 25 mg mg 25 mg mg 100 mg 1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Analysis of safety The analysis was performed on the Total Vaccinated cohort.

Analysis of safety The analysis was performed on the Total Vaccinated cohort. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Analysis of immunogenicity

Analysis of immunogenicity The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-

Study No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary- The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study

Study No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory

More information

Soleus 75 (6 ml) 0 (6 ml) 75 (6 ml. Tibialis posterior 75 (6 ml) 0 (6 ml) 75 (6 ml) Total 300 (24 ml) 0 (24 ml) 300 (24 ml) Dose: U (solution volume)

Soleus 75 (6 ml) 0 (6 ml) 75 (6 ml. Tibialis posterior 75 (6 ml) 0 (6 ml) 75 (6 ml) Total 300 (24 ml) 0 (24 ml) 300 (24 ml) Dose: U (solution volume) Study No.: BTX108512 Title: A Multicenter Study to Evaluate the Efficacy and Safety in Patients with Post-Stroke lower Limb Spasticity Receiving a Double-Blind, -Controlled GSK1358820 Treatment Followed

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

The only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2

The only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2 The only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2 Trelegy Ellipta is indicated for maintenance treatment in adult patients with moderate-to-severe

More information

SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).

SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers). Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Study No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline

umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline 04 July 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number:

GSK Medicine: Study Number: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Clinical trial phase. Study Start/End Dates.

Sponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Clinical trial phase. Study Start/End Dates. Sponsor Novartis Generic drug name Fluticasone propionate Trial indication(s) Moderate-severe bronchial asthma Protocol number CQAE397A2202 Protocol title A randomized open label study to assess the utility

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with

More information

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14) The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SYNOPSIS. Date 15 June 2004

SYNOPSIS. Date 15 June 2004 Drug product Drug substance(s) Document No. Edition No. Study code SYMBICORT pmdi 160/4.5 mg per actuation Budesonide/formoterol SD-039-0719 Date 15 June 2004 SYNOPSIS A Six-Month, Randomized, Open-Label

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: he study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Evidence Summary to support COPD formulary decision making and guideline development

Evidence Summary to support COPD formulary decision making and guideline development Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final pages of this document. Anoro, and Ellipta

More information

Decramer 2014 a &b [21]

Decramer 2014 a &b [21] Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH

More information

InforMing the PAthway of COPD Treatment 1

InforMing the PAthway of COPD Treatment 1 InforMing the PAthway of COPD Treatment 1 A landmark trial in over 10,000 symptomatic COPD patients who had experienced at least one exacerbation in the last 12 months 1 (fluticasone furoate/umeclidinium/vilanterol)

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Trial Results Summary Study EN3409-BUP-305

Clinical Trial Results Summary Study EN3409-BUP-305 Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Group 1 (Test Group) Group 2 (Reference group):

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Group 1 (Test Group) Group 2 (Reference group): The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Incruse Ellipta 55mcg (umeclidinium bromide) for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD):

Incruse Ellipta 55mcg (umeclidinium bromide) for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD): Incruse Ellipta 55mcg (umeclidinium bromide) for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD): An introduction for Clinical Commisioning Groups and Health

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Pulmonary Pathophysiology

Pulmonary Pathophysiology Pulmonary Pathophysiology 1 Reduction of Pulmonary Function 1. Inadequate blood flow to the lungs hypoperfusion 2. Inadequate air flow to the alveoli - hypoventilation 2 Signs and Symptoms of Pulmonary

More information

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s):

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s): The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia

Sponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia Page 1 Sponsor Novartis Generic Drug Name Fluvastatin Therapeutic Area of Trial Dyslipidemia Approved Indication Therapeutic area and approved indications in Germany: Hypercholesterolemia (HC), combined

More information